Q-omics provides the consensus-scored MAP1LC3C profile across patient tissues and cancer cell-line models. MAP1LC3C expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, MAP1LC3C is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, MAP1LC3C RNA expression shows 18,847 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UCEC, THCA, and LSCC as cancer lineages where MAP1LC3C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAP1LC3C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAP1LC3C survival associations across molecular data types. MAP1LC3C RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAP1LC3C RNA expression–survival associations across cancer types. High MAP1LC3C expression shows unfavorable associations in UCEC, LUSC and LGG, but favorable associations in UVM, HNSC and LUAD. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for MAP1LC3C RNA expression.
This table summarizes MAP1LC3C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MAP1LC3C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAP1LC3C shows lower tumor expression in THCA, HNSC, LUSC and LUAD and higher tumor expression in KIRP and KIRC. The THCA box plot shows higher MAP1LC3C RNA expression in normal versus tumor tissue (log2 FC = −1.338, t-test p < 0.001).
This table shows molecular features associated with MAP1LC3C in patient tissues and cancer cell lines. In patient samples, MAP1LC3C shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MAP1LC3C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
